Exact Mass: 433.17365820000003
Exact Mass Matches: 433.17365820000003
Found 237 metabolites which its exact mass value is equals to given mass value 433.17365820000003
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Meleagrine
C23H23N5O4 (433.17499580000003)
An indole alkaloid with a heterotetracyclic skeleton isolated from Penicillium oxalicum.
Brexpiprazole
C25H27N3O2S (433.18238820000005)
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
C24H23N3O5 (433.16376280000003)
Sarpicillin
C21H27N3O5S (433.1671332000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
Fenfangjine G
C22H27NO8 (433.17365820000003)
(1R)-(4-hydroxybenzyl)-7-hydroxyl-8-O-beta-D-glucopyranosyl-1,2,3,4-tetrahydroisoquinoline
C22H27NO8 (433.17365820000003)
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
C23H28ClNO5 (433.1655908000001)
C23H23N5O4_(3Z)-6-Hydroxy-3-(1H-imidazol-5-ylmethylene)-12-methoxy-7a-(2-methyl-3-buten-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
C23H23N5O4 (433.17499580000003)
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]
C23H28ClNO5 (433.1655908000001)
[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]
C23H28ClNO5 (433.1655908000001)
Ala Asp Gln Thr
C16H27N5O9 (433.18086919999996)
Ala Asp Thr Gln
C16H27N5O9 (433.18086919999996)
Ala Glu Asn Thr
C16H27N5O9 (433.18086919999996)
Ala Glu Gln Ser
C16H27N5O9 (433.18086919999996)
Ala Glu Ser Gln
C16H27N5O9 (433.18086919999996)
Ala Glu Thr Asn
C16H27N5O9 (433.18086919999996)
Ala Asn Glu Thr
C16H27N5O9 (433.18086919999996)
Ala Asn Thr Glu
C16H27N5O9 (433.18086919999996)
Ala Gln Asp Thr
C16H27N5O9 (433.18086919999996)
Ala Gln Glu Ser
C16H27N5O9 (433.18086919999996)
Ala Gln Ser Glu
C16H27N5O9 (433.18086919999996)
Ala Gln Thr Asp
C16H27N5O9 (433.18086919999996)
Ala Ser Glu Gln
C16H27N5O9 (433.18086919999996)
Ala Ser Gln Glu
C16H27N5O9 (433.18086919999996)
Ala Thr Asp Gln
C16H27N5O9 (433.18086919999996)
Ala Thr Glu Asn
C16H27N5O9 (433.18086919999996)
Ala Thr Asn Glu
C16H27N5O9 (433.18086919999996)
Ala Thr Gln Asp
C16H27N5O9 (433.18086919999996)
Asp Ala Gln Thr
C16H27N5O9 (433.18086919999996)
Asp Ala Thr Gln
C16H27N5O9 (433.18086919999996)
Asp Asp Gly Lys
C16H27N5O9 (433.18086919999996)
Asp Asp Lys Gly
C16H27N5O9 (433.18086919999996)
Asp Gly Asp Lys
C16H27N5O9 (433.18086919999996)
Asp Gly Lys Asp
C16H27N5O9 (433.18086919999996)
Asp Lys Asp Gly
C16H27N5O9 (433.18086919999996)
Asp Lys Gly Asp
C16H27N5O9 (433.18086919999996)
Asp Asn Ser Val
C16H27N5O9 (433.18086919999996)
Asp Asn Val Ser
C16H27N5O9 (433.18086919999996)
Asp Gln Ala Thr
C16H27N5O9 (433.18086919999996)
Asp Gln Thr Ala
C16H27N5O9 (433.18086919999996)
Asp Ser Asn Val
C16H27N5O9 (433.18086919999996)
Asp Ser Val Asn
C16H27N5O9 (433.18086919999996)
Asp Thr Ala Gln
C16H27N5O9 (433.18086919999996)
Asp Thr Gln Ala
C16H27N5O9 (433.18086919999996)
Asp Val Asn Ser
C16H27N5O9 (433.18086919999996)
Asp Val Ser Asn
C16H27N5O9 (433.18086919999996)
Glu Ala Asn Thr
C16H27N5O9 (433.18086919999996)
Glu Ala Gln Ser
C16H27N5O9 (433.18086919999996)
Glu Ala Ser Gln
C16H27N5O9 (433.18086919999996)
Glu Ala Thr Asn
C16H27N5O9 (433.18086919999996)
Glu Gly Gln Thr
C16H27N5O9 (433.18086919999996)
Glu Gly Thr Gln
C16H27N5O9 (433.18086919999996)
Glu Asn Ala Thr
C16H27N5O9 (433.18086919999996)
Glu Asn Thr Ala
C16H27N5O9 (433.18086919999996)
Glu Gln Ala Ser
C16H27N5O9 (433.18086919999996)
Glu Gln Gly Thr
C16H27N5O9 (433.18086919999996)
Glu Gln Ser Ala
C16H27N5O9 (433.18086919999996)
Glu Gln Thr Gly
C16H27N5O9 (433.18086919999996)
Glu Ser Ala Gln
C16H27N5O9 (433.18086919999996)
Glu Ser Gln Ala
C16H27N5O9 (433.18086919999996)
Glu Thr Ala Asn
C16H27N5O9 (433.18086919999996)
Glu Thr Gly Gln
C16H27N5O9 (433.18086919999996)
Glu Thr Asn Ala
C16H27N5O9 (433.18086919999996)
Glu Thr Gln Gly
C16H27N5O9 (433.18086919999996)
Gly Asp Asp Lys
C16H27N5O9 (433.18086919999996)
Gly Asp Lys Asp
C16H27N5O9 (433.18086919999996)
Gly Glu Gln Thr
C16H27N5O9 (433.18086919999996)
Gly Glu Thr Gln
C16H27N5O9 (433.18086919999996)
Gly Lys Asp Asp
C16H27N5O9 (433.18086919999996)
Gly Gln Glu Thr
C16H27N5O9 (433.18086919999996)
Gly Gln Thr Glu
C16H27N5O9 (433.18086919999996)
Gly Thr Glu Gln
C16H27N5O9 (433.18086919999996)
Gly Thr Gln Glu
C16H27N5O9 (433.18086919999996)
Lys Asp Asp Gly
C16H27N5O9 (433.18086919999996)
Lys Asp Gly Asp
C16H27N5O9 (433.18086919999996)
Lys Gly Asp Asp
C16H27N5O9 (433.18086919999996)
Asn Ala Glu Thr
C16H27N5O9 (433.18086919999996)
Asn Ala Thr Glu
C16H27N5O9 (433.18086919999996)
Asn Asp Ser Val
C16H27N5O9 (433.18086919999996)
Asn Asp Val Ser
C16H27N5O9 (433.18086919999996)
Asn Glu Ala Thr
C16H27N5O9 (433.18086919999996)
Asn Glu Thr Ala
C16H27N5O9 (433.18086919999996)
Asn Ser Asp Val
C16H27N5O9 (433.18086919999996)
Asn Ser Val Asp
C16H27N5O9 (433.18086919999996)
Asn Thr Ala Glu
C16H27N5O9 (433.18086919999996)
Asn Thr Glu Ala
C16H27N5O9 (433.18086919999996)
Asn Val Asp Ser
C16H27N5O9 (433.18086919999996)
Asn Val Ser Asp
C16H27N5O9 (433.18086919999996)
Gln Ala Asp Thr
C16H27N5O9 (433.18086919999996)
Gln Ala Glu Ser
C16H27N5O9 (433.18086919999996)
Gln Ala Ser Glu
C16H27N5O9 (433.18086919999996)
Gln Ala Thr Asp
C16H27N5O9 (433.18086919999996)
Gln Asp Ala Thr
C16H27N5O9 (433.18086919999996)
Gln Asp Thr Ala
C16H27N5O9 (433.18086919999996)
Gln Glu Ala Ser
C16H27N5O9 (433.18086919999996)
Gln Glu Gly Thr
C16H27N5O9 (433.18086919999996)
Gln Glu Ser Ala
C16H27N5O9 (433.18086919999996)
Gln Glu Thr Gly
C16H27N5O9 (433.18086919999996)
Gln Gly Glu Thr
C16H27N5O9 (433.18086919999996)
Gln Gly Thr Glu
C16H27N5O9 (433.18086919999996)
Gln Ser Ala Glu
C16H27N5O9 (433.18086919999996)
Gln Ser Glu Ala
C16H27N5O9 (433.18086919999996)
Gln Thr Ala Asp
C16H27N5O9 (433.18086919999996)
Gln Thr Asp Ala
C16H27N5O9 (433.18086919999996)
Gln Thr Glu Gly
C16H27N5O9 (433.18086919999996)
Gln Thr Gly Glu
C16H27N5O9 (433.18086919999996)
Ser Ala Glu Gln
C16H27N5O9 (433.18086919999996)
Ser Ala Gln Glu
C16H27N5O9 (433.18086919999996)
Ser Asp Asn Val
C16H27N5O9 (433.18086919999996)
Ser Asp Val Asn
C16H27N5O9 (433.18086919999996)
Ser Glu Ala Gln
C16H27N5O9 (433.18086919999996)
Ser Glu Gln Ala
C16H27N5O9 (433.18086919999996)
Ser Asn Asp Val
C16H27N5O9 (433.18086919999996)
Ser Asn Val Asp
C16H27N5O9 (433.18086919999996)
Ser Gln Ala Glu
C16H27N5O9 (433.18086919999996)
Ser Gln Glu Ala
C16H27N5O9 (433.18086919999996)
Ser Val Asp Asn
C16H27N5O9 (433.18086919999996)
Ser Val Asn Asp
C16H27N5O9 (433.18086919999996)
Thr Ala Asp Gln
C16H27N5O9 (433.18086919999996)
Thr Ala Glu Asn
C16H27N5O9 (433.18086919999996)
Thr Ala Asn Glu
C16H27N5O9 (433.18086919999996)
Thr Ala Gln Asp
C16H27N5O9 (433.18086919999996)
Thr Asp Ala Gln
C16H27N5O9 (433.18086919999996)
Thr Asp Gln Ala
C16H27N5O9 (433.18086919999996)
Thr Glu Ala Asn
C16H27N5O9 (433.18086919999996)
Thr Glu Gly Gln
C16H27N5O9 (433.18086919999996)
Thr Glu Asn Ala
C16H27N5O9 (433.18086919999996)
Thr Glu Gln Gly
C16H27N5O9 (433.18086919999996)
Thr Gly Glu Gln
C16H27N5O9 (433.18086919999996)
Thr Gly Gln Glu
C16H27N5O9 (433.18086919999996)
Thr Asn Ala Glu
C16H27N5O9 (433.18086919999996)
Thr Asn Glu Ala
C16H27N5O9 (433.18086919999996)
Thr Gln Ala Asp
C16H27N5O9 (433.18086919999996)
Thr Gln Asp Ala
C16H27N5O9 (433.18086919999996)
Thr Gln Glu Gly
C16H27N5O9 (433.18086919999996)
Thr Gln Gly Glu
C16H27N5O9 (433.18086919999996)
Val Asp Asn Ser
C16H27N5O9 (433.18086919999996)
Val Asp Ser Asn
C16H27N5O9 (433.18086919999996)
Val Asn Asp Ser
C16H27N5O9 (433.18086919999996)
Val Asn Ser Asp
C16H27N5O9 (433.18086919999996)
Val Ser Asp Asn
C16H27N5O9 (433.18086919999996)
Val Ser Asn Asp
C16H27N5O9 (433.18086919999996)
6-(methylamino)hexane-1,2,3,4,5-pentol,4-(2H-tetrazol-5-yl)tetrazolo[1,5-a]quinoline
1H-Pyrazole-4-carboxamide,5-chloro-N-[2-[(3,7-dimethyl-2-quinolinyl)amino]ethyl]-3-methyl-1-phenyl-(9CI)
Sarpicillin
C21H27N3O5S (433.1671332000001)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
3-[[4-(diethylamino)phenyl]azo]-1,2-dimethyl-1H-indazolium methyl sulphate
C20H27N5O4S (433.1783662000001)
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-(4-fluorophenyl)-N-(3-pyridinylmethyl)- (9CI)
(S)-(4-(3-(BENZYLOXY)-2-(((BENZYLOXY)CARBONYL)AMINO)-3-OXOPROPYL)PHENYL)BORONIC ACID
Methyl (3R,4S)-1-(4-fluorophenyl)-2-oxo-4-[4-(phenylmethoxy)phenyl]-3-azetidinepropanoate
Fluvastatin sodium
C24H25FNNaO4 (433.16652220000003)
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer?of Fluvastatin. Fluvastatin is a first fully synthetic, competitive?HMG-CoA reductase?inhibitor with an IC50?of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1].
(4-Nitrophenyl) 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylate
C24H23N3O5 (433.16376280000003)
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively[1].
(3r,5s)-Fluvastatin sodium
C24H25FNNaO4 (433.16652220000003)
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors (3R,5S)-Fluvastatin ((3R,5S)-XU 62-320) sodium is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
N-(2,4-dimethoxyphenyl)-2-[1-(3,4-dimethylphenyl)-4-oxo-5-pyrazolo[3,4-d]pyrimidinyl]acetamide
C23H23N5O4 (433.17499580000003)
5-[(3,4-Dimethoxyphenyl)-[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-methyl-6-thiazolo[3,2-b][1,2,4]triazolol
C20H27N5O4S (433.1783662000001)
Brexpiprazole
C25H27N3O2S (433.18238820000005)
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].
(3Z)-3-[(2E,4E,6R)-1-hydroxy-6-[(2S,7R,8R)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.02,4]decan-8-yl]-4-methylhepta-2,4-dienylidene]pyrrolidine-2,4-dione
C22H27NO8 (433.17365820000003)
(3E,7aS,12aR)-6-hydroxy-3-(1H-imidazol-4-ylmethylidene)-12-methoxy-7a-(2-methylbut-3-en-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione
C23H23N5O4 (433.17499580000003)
4-chloro-N-[2-(1H-indol-3-yl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)ethyl]benzamide
3-(3,4,5-Trimethoxyphenyl)propanoic acid [2-(3,5-dimethoxyanilino)-2-oxoethyl] ester
C22H27NO8 (433.17365820000003)
7-[(2-Chloro-6-fluorophenyl)methyl]-1,3-dimethyl-8-[(3-methyl-1-piperidinyl)methyl]purine-2,6-dione
4-[2-Benzofuranyl(oxo)methyl]-1-[2-(4-morpholinyl)ethyl]-5-(3-pyridinyl)pyrrolidine-2,3-dione
C24H23N3O5 (433.16376280000003)
(2S,3S,3aR,9bR)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-(4-fluorophenyl)-3-(hydroxymethyl)-1-methyl-6-oxo-N-phenyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1R,9S,10S,11S)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1S,9R,10R,11R)-N-benzyl-5-(3-fluorophenyl)-10-(hydroxymethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
cyclobutyl-[(1S)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C21H27N3O5S (433.1671332000001)
cyclobutyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-methylsulfonyl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
C21H27N3O5S (433.1671332000001)
Fluvastatin (sodium)
C24H25FNNaO4 (433.16652220000003)
Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway[1][2][3].
Izilendustat
C22H28ClN3O4 (433.1768238000001)
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1)[1][1].
(7s)-5-chloro-3-[(1e,3e,5r)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(1s,8r,9r,12s,13r)-12-(acetyloxy)-3,8-dihydroxy-4,11-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5,10-tetraen-13-yl acetate
C22H27NO8 (433.17365820000003)
11-(5-{[(3-carboxy-1-hydroxy-3-methylpropylidene)amino]carbonyl}-4-oxopyran-2-yl)undeca-8,10-dienoic acid
C22H27NO8 (433.17365820000003)
5-({4,5-bis[(4-methoxyphenyl)methyl]imidazol-2-ylidene}amino)-3-methylimidazole-2,4-diol
C23H23N5O4 (433.17499580000003)
(4z)-5-hydroxy-4-[(2e,4e,6r)-1-hydroxy-6-[(1s,2s,4r,6s,7r,8r)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dien-1-ylidene]-2h-pyrrol-3-one
C22H27NO8 (433.17365820000003)
(2z)-3-[(2r,3's,3'as,8'ar)-3'-ethyl-4-methyl-4',5-dioxo-3',3'a,6',7',8',8'a-hexahydrospiro[furan-2,2'-furo[3,2-c]azepin]-5'-yl]-3-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]prop-2-enoic acid
C22H27NO8 (433.17365820000003)
(7r)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
5-({4,5-bis[(4-methoxyphenyl)methyl]-1h-imidazol-2-yl}imino)-2-hydroxy-3-methylimidazol-4-one
C23H23N5O4 (433.17499580000003)
(7r)-5-chloro-3-[(1e,3z,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(1s,9r)-12-(acetyloxy)-3,8-dihydroxy-4,11-dimethoxy-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5,10-tetraen-13-yl acetate
C22H27NO8 (433.17365820000003)
(8e,10e)-11-[5-({[(3s)-3-carboxy-1-hydroxy-3-methylpropylidene]amino}carbonyl)-4-oxopyran-2-yl]undeca-8,10-dienoic acid
C22H27NO8 (433.17365820000003)
8-({2-carboxy-2-[(1-hydroxyethylidene)amino]ethyl}sulfanyl)-3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1,2-dihydroxy-1-methyl-2,3-dihydro-4λ⁵-indolizin-4-ylium
[C22H29N2O5S]+ (433.17970840000004)
2-hydroxy-5-({5-[(4-hydroxyphenyl)methyl]-4-[(4-methoxyphenyl)methyl]-1-methylimidazol-2-yl}imino)-3-methylimidazol-4-one
C23H23N5O4 (433.17499580000003)
2-{4-[(6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
C22H27NO8 (433.17365820000003)
11-hydroxy-14-(1h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10-tetraene-12,15-dione
C23H23N5O4 (433.17499580000003)
(1s,9s,14z)-11,15-dihydroxy-14-(3h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C23H23N5O4 (433.17499580000003)
(14e)-11,15-dihydroxy-14-(3h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C23H23N5O4 (433.17499580000003)
5-hydroxy-4-[(6r)-1-hydroxy-6-[(1s,2s,4r,6s,7r,8r)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dien-1-ylidene]-2h-pyrrol-3-one
C22H27NO8 (433.17365820000003)
5-hydroxy-4-{1-hydroxy-6-[2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dien-1-ylidene}-2h-pyrrol-3-one
C22H27NO8 (433.17365820000003)
(14z)-11,15-dihydroxy-14-(3h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C23H23N5O4 (433.17499580000003)
5-hydroxy-4-[(2e,4e)-6-[2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dienoyl]-1,2-dihydropyrrol-3-one
C22H27NO8 (433.17365820000003)
(1s,2s,3s)-8-{[(2r)-2-carboxy-2-[(1-hydroxyethylidene)amino]ethyl]sulfanyl}-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1,2-dihydroxy-1-methyl-2,3-dihydro-4λ⁵-indolizin-4-ylium
[C22H29N2O5S]+ (433.17970840000004)
(1r,9s)-11-hydroxy-14-(1h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10-tetraene-12,15-dione
C23H23N5O4 (433.17499580000003)
(1s,9r,14e)-11,15-dihydroxy-14-(3h-imidazol-4-ylmethylidene)-2-methoxy-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C23H23N5O4 (433.17499580000003)
(4z)-5-hydroxy-4-[(2e,4e,6r)-1-hydroxy-6-[(1s,2r,4s,6s,7r,8r)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dien-1-ylidene]-2h-pyrrol-3-one
C22H27NO8 (433.17365820000003)
(7s)-5-chloro-3-[(1e,3e,5s)-3,5-dimethylhepta-1,3-dien-1-yl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(2r,3s,4r,5r,6s)-2-(4-{[(1s)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
C22H27NO8 (433.17365820000003)
5-chloro-3-(3,5-dimethylhepta-1,3-dien-1-yl)-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl acetate
C23H28ClNO5 (433.1655908000001)
(4z)-5-hydroxy-4-[(2e,4e,6r)-1-hydroxy-6-[(1r,2r,4s,6r,7s,8s)-2-(hydroxymethyl)-1,7-dimethyl-5-oxo-3,9,10-trioxatricyclo[4.3.1.0²,⁴]decan-8-yl]-4-methylhepta-2,4-dien-1-ylidene]-2h-pyrrol-3-one
C22H27NO8 (433.17365820000003)